Long-term intraocular pressure changes after intravitreal injection of bevacizumab

References

• Kliffen M, Sharma HS, Mooy CM, et al. Increased expression of angiogenic growth factors in age-related maculopathy. Br J Ophthalmol 1997;81:154–162.
   PubMed Web of Science ®Google Scholar
• Research Group CATT. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897–1908.
   PubMed Web of Science ®Google Scholar
• Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388–1398.
   PubMed Web of Science ®Google Scholar
• Epstein DL, Algvere PV, von Wendt G, et al. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study. Ophthalmology 2012;119:1184–1189.
   PubMed Web of Science ®Google Scholar
• Harder BC, Schlichtenbrede FC, von Baltz S, et al. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results. Am J Ophthalmol 2013;155:1119–1124.
   PubMed Web of Science ®Google Scholar
• Stein JD, Newman-Casey PA, Kim DD, et al. Cost-effectiveness of various interventions for newly diagnosed diabetic macular edema. Ophthalmology 2013;120:1835–1842.
   PubMed Web of Science ®Google Scholar
• Tseng JJ, Vance SK, Della Torre KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21:241–247.
   PubMed Web of Science ®Google Scholar
• Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther 2010;26:105–110.
   PubMed Web of Science ®Google Scholar
• Good TJ, Kimura AE, Mandava N, Kahook MY. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol 2011;95:1111–1114.
   PubMed Web of Science ®Google Scholar
• Gismondi M, Salati C, Salvetat ML, et al. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009;18:658–661.
   PubMed Web of Science ®Google Scholar
• Hollands H, Wong J, Bruen R, et al. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007;42:807–811.
   PubMed Web of Science ®Google Scholar
• Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008;146:930–941.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Pulido JS, McCannel CA, et al. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009;23:181–185.
   PubMed Web of Science ®Google Scholar
• Kahook MY, Kimura AE, Wong LJ, et al. Sustained elevation in intraocular pressure associated with intravitreal bevacizumab injections. Ophthalmic Surg Lasers Imaging 2009;40:293–295.
   PubMed Web of Science ®Google Scholar
• Bakri SJ, McCannel CA, Edwards AO, Moshfeghi DM. Persisent ocular hypertension following intravitreal ranibizumab. Graefes Arch Clin Exp Ophthalmol 2008;246:955–958.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Sung KR, Lee KS, et al. Long-term effects of multiple intravitreal antivascular endothelial growth factor injection on intraocular pressure. Am J Ophthalmol 2014;157:1266–1271.
   PubMed Web of Science ®Google Scholar
• Hoang QV, Mendonca LS, Della Torre KE, et al. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012;119:321–326.
   PubMed Web of Science ®Google Scholar
• Klein BE, Klein R, Linton KL. Intraocular pressure in an American community. The Beaver Dam Eye Study. Invest Ophthalmol Vis Sci 1992;33:2224–2248.
   PubMed Web of Science ®Google Scholar
• Wu SY, Leske MC. Associations with intraocular pressure in the Barbados Eye Study. Arch Ophthalmol 1997;115:1572–1576.
   PubMed Web of Science ®Google Scholar
• Nakano T, Tatemichi M, Miura Y, et al. Long-term physiologic changes of intraocular pressure: a 10-year longitudinal analysis in young and middle-aged Japanese men. Ophthalmology 2005;112:609–616.
   PubMed Web of Science ®Google Scholar
• Engelbert M, Zweifel SA, Freund KB. “Treat and extend” dosing of intravitreal antivascular endothelial growth factor therapy for type 3 neovascularization/retinal angiomatous proliferation. Retina 2009;29:1424–1431.
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET, Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Eng J Med 2004;351:2805–2816.
   PubMed Web of Science ®Google Scholar
• VEGF Inhibition Study in Ocular Neovascularization (V. I. S.I.O.N.) Clinical Trial Group. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Opthalmology 2006;113:992–1001.
   PubMed Web of Science ®Google Scholar
• Hyman L. Myopic and hyperopic refractive error in adults: an overview. Ophthalmic Epidemiol 2007;14:192–197.
   PubMed Web of Science ®Google Scholar
• Saw SM. A synopsis of the prevalence rates and environmental risk factors for myopia. Clin Exp Optom 2003;86:289–294.
   PubMedGoogle Scholar
• Georgopoulos M, Polak K, Prager F, et al. Characteristics of severe intraocular inflammation following intravitreal injection of bevacizumab (Avastin). Br J Ophthalmol 2009;93:457–462.
   PubMed Web of Science ®Google Scholar
• Liu L, Ammar DA, Ross LA, et al. Silicone oil microdroplets and protein aggregates in repackaged bevacizumab and ranibizumab: effects of long-term storage and product mishandling. Invest Ophthalmol Vis Sci 2011;52:1023–1034.
   PubMed Web of Science ®Google Scholar
• Hoang QV, Jung JJ, Mrejen S, Freund KB. Influence of axial length and postinjection reflux on sustained intraocular pressure elevation as a result of intravitreal anti-vascular endothelial growth factor therapy. Retina 2014;34:519–524.
   PubMed Web of Science ®Google Scholar
• Ladas JG, Yu F, Loo R, et al. Relationship between aqueous humor protein level and outflow facility in patients with uveitis. Invest Ophthalmol Vis Sci 2001;42:2584–2588.
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419–1431.
   PubMed Web of Science ®Google Scholar
• Stewart MW. Anti-VEGF therapy for diabetic macular edema. Curr Diab Rep 2014;14:510.
   PubMed Web of Science ®Google Scholar
• Liu JH, Kripke DF, Twa MD, et al. Twenty-four-hour pattern of intraocular pressure in the aging population. Invest Ophthalmol Vis Sci 1999;40:2912–2917.
   PubMed Web of Science ®Google Scholar
• Reiss GR, Lee DA, Topper JE, Brubaker RF. Aqueous humor flow during sleep. Invest Ophthalmol Vis Sci 1984;25:776–778.
   PubMed Web of Science ®Google Scholar
• Mathalone N, Arodi-Golan A, Sar S, et al. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2012;250:1435–1440.
   PubMed Web of Science ®Google Scholar